Finance
e-Newsletter
Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

Lower sales of Tysabri predicted

Boston Globe, August 6, 2008

It is expected that fewer patients will be taking Tysabri, used to treat multiple sclerosis, as two more patients have been diagnosed with a potentially fatal brain disease. Financial analysts predict that the drug will have only about 75,000 users by 2013, which is below Biogen Idec Inc.'s goal of 100,000.